Previous 10 | Next 10 |
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) posted briefing documents for the March 30, 2022 Peripheral and Central Nervous System Drugs Advisory Committee (PCNSDAC) ...
The shares of clinical-stage biotech, Amylyx Pharmaceuticals (NASDAQ:AMLX), are currently on hold after the U.S. Food and Drug Administration (FDA) released staff documents ahead of an AdCom meeting convened to discuss the company’s amyotrophic lateral sclerosis therapy AMX00...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
Amylyx Pharmaceuticals (AMLX) shares shot up 20% in midday trading Friday. Shares of the biotech company, which is developing a treatment for ALS, opened at $22.79, dipping to a low of $21.71 before hitting a high of $26.95 midday. The stock last changed hands at $26.13, up 20%, at approximat...
Gainers: Clever Leaves Holdings (CLVR) +33%. NextDecade (NEXT) +23%. Dynagas LNG (DLNG) +23%. Clarus Therapeutics (CRXT) +23%. Amylyx (AMLX) +20%. Hoegh LNG Partners LP (HMLP) +21%. Kidpik (PIK) +19%. Agrify (AGFY) +17%. NexImmune (NEXI) +17%. Joby Aviation (JOBY) +17%. Losers: Icosavax (ICVX...
Amylyx Pharmaceuticals (NASDAQ:AMLX) launched an Expanded Access Program (EAP) for AMX0035 in the U.S. for people with amyotrophic lateral sclerosis (ALS) that meet program eligibility criteria. The company said EAPs are designed to give access to potential therapies before they are...
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) announced today the launch of an Expanded Access Program (EAP) for AMX0035 (sodium phenylbutyrate [PB] and taurursodiol [TURSO; also known as ursodoxicoltaurine]) in the U.S. for people l...
Halvorsen's 13F portfolio value decreased from $36.04B to $34.49B this quarter. The number of positions increased from 96 to 107. Viking Global added Twilio, Workday, and Aon plc while dropping Fidelity National Information Services and Snowflake. The top three positions are Ginkg...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotech stocks had a so-so year in 2021, as the Covid-19-induced boost the sector received in the previous year wore off. The iShares Biotechnology ETF (NASDAQ: IBB ), which is considered a proxy for the sector, gaine...
Vancouver, Kelowna, Delta, BC - February 25, 2022 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces its weekly roundup of stocks to watch in Biotech, Cannabis and Mining. Today's stocks have been added to our lists of free sto...
News, Short Squeeze, Breakout and More Instantly...
Amylyx Pharmaceuticals Inc. Company Name:
AMLX Stock Symbol:
NASDAQ Market:
Amylyx Pharmaceuticals Inc. Website:
- Avexitide is a novel, first-in-class GLP-1 receptor antagonist with the potential to treat hyperinsulinemic hypoglycemia - FDA Breakthrough Therapy Designation granted for avexitide for post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism - Acquisition builds on Am...
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced that Amylyx’ management team will host a conference call and webcast tomorrow, Wednesday, July 10, 2024, at 8:00 a.m. ET to discuss the acquisition of avexitide from Eiger ...
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that management will participate in a fireside chat presentation at the Goldman Sachs 45th Annual Global Healthcare Conference. The conference is being conducted in-person in Miam...